Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study

SUMMARY: Zoledronic acid (ZOL) is a therapy inhibiting bone resorption. In this study, generic ZOL (Yigu®) showed its clinical efficacy consistency with original ZOL (Aclasta®) in Chinese postmenopausal women with osteoporosis. This study provides a practical basis for the application of Yigu® in Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mei, Cheng, Qun, Huo, Ya-nan, Chao, Ai-jun, He, Liang, Xue, Qing-yun, Xu, Jin, Yan, Shi-gui, Jin, Hui, Zhang, Zhen-lin, Lin, Jian-hua, Jin, Xiao-lan, Xu, You-jia, Liu, Feng, Xia, Wei-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755672/
https://www.ncbi.nlm.nih.gov/pubmed/35020038
http://dx.doi.org/10.1007/s11657-021-01052-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755672/
https://www.ncbi.nlm.nih.gov/pubmed/35020038
http://dx.doi.org/10.1007/s11657-021-01052-y

Ejemplares similares